ADCTAdc Therapeutics SA
$1.19
$0.05
(4.39%)
Closed $1.19
$0.02
(1.68%)
After Hours
EarningsAug 5
Mkt Cap$151.36M
Vol1.8M
ADC Therapeutics Announces New Employee Inducement Grant
ADC Therapeutics Announces New Employee Inducement Grant ADC Therapeutics Announces New Employee Inducement Grant PR Newswire LAUSANNE, Switzerland, July 1, 2026 LAUSANNE, Switzerland, July 1, 2026 /PRNewswire/ --ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the...
PR Newswire
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA Combination Trial
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA Combination Trial ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA Combination Trial PR Newswire LAUSANNE, Switzerland, June 30, 2026 100 r/r DLBCL patients treated at the selected 150...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT PR Newswire NEW YORK, June 25, 2026 NEW YORK, June 25, 2026 /PRNewswire...
PR Newswire
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA Growth Opportunities and Regulatory Priorities
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA Growth Opportunities and Regulatory Priorities ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA Growth Opportunities and Regulatory Priorities PR Newswire LAUSANNE, Switzerland, June 24, 2026 Planned ~17...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT PR Newswire NEW YORK, June 18, 2026 NEW YORK, June 18, 2026 /PRNewswire...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT PR Newswire NEW YORK, June 11, 2026 NEW YORK, June 11, 2026 /PRNewswire...
PR Newswire
ADC Therapeutics Tumbles On Phase 3 Trial Safety Concerns, Joins Other Big Stocks Moving Lower In Thursday's Pre-Market Session (CORRECTED)
U.S. stock futures down on tech profit-taking and weak guidance, ADC Therapeutics shares plunge 50.67%, other stocks also slide.read more...
Benzinga
Why Is ADC Therapeutics Stock Falling On Friday?
Discover why ADC Therapeutics (NYSE:ADCT) stock is tumbling on Friday as a prominent Wall Street analyst slashes targets due to serious trial safety signals.read more...
Benzinga
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data
ADC Therapeutics stock plunges 53% after-hours as investors focus on safety concerns in a phase III DLBCL study of Zynlonta, despite meeting its primary efficacy goal.
Zacks
<
1
2
...
>
Advertisement|Remove ads.
Latest ADCT News
ViewADC Therapeutics Announces New Employee Inducement Grant
PR Newswire
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA Combination Trial
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
PR Newswire
Advertisement|Remove ads.